Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Patrick M Forde; Jonathan Spicer; Shun Lu; Mariano Provencio; Tetsuya Mitsudomi; Mark M. Awad; Enriqueta Felip; Stephen R Broderick; Julie R. Brahmer; Scott J. Swanson; Keith Kerr; Changli Wang; Tudor-Eliade Ciuleanu; Gene B. Saylors; Fumihiro Tanaka; Hiroyuki Ito; Ke-Neng Chen; Moishe Liberman; Everett E. Vokes; Janis M. Taube; Cecile Dorange; Jun-Liang Cai; Joseph Fiore; Anthony Jarkowski; David Balli; Mark Sausen; Dimple Pandya; Christophe Y. Calvet; Nicolas Girard

doi:10.1056/nejmoa2202170

Abstract

In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone. The addition of nivolumab to neoadjuvant chemotherapy did not increase the incidence of adverse events or impede the feasibility of surgery. (Funded by Bristol Myers Squibb; CheckMate 816 ClinicalTrials.gov number, NCT02998528.).

MeSH Terms

Antineoplastic AgentsAntineoplastic AgentsImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinomaNon-Small-Cell LungHumansIpilimumabLung NeoplasmsNeoadjuvant TherapyNeoplasm RecurrenceLocalNivolumabPlatinum Compounds

Affiliated Institutions

Related Publications

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer , Karen L. Reckamp , Paul Baas +22 more

Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab tha...

2015 New England Journal of Medicine 8355 citations

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann , Luis Paz‐Ares , Reyes Bernabé +23 more

First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expr...

2019 New England Journal of Medicine 2696 citations

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei , L. Paz-Ares , Leora Horn +25 more

Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (...

2015 New England Journal of Medicine 9225 citations

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

David P. Carbone , Martin Reck , Luis Paz‐Ares +26 more

Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD...

2017 New England Journal of Medicine 2526 citations

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok , Vanna Chiarion‐Sileni , René González +30 more

Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with i...

2017 New England Journal of Medicine 5260 citations

Publication Info

Year: 2022
Type: article
Volume: 386
Issue: 21
Pages: 1973-1985
Citations: 2157
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2157

OpenAlex

144

Influential

2018

CrossRef

Cite This

APA Style

                            
                                
                                    Patrick M Forde, 
                                
                                    Jonathan Spicer, 
                                
                                    Shun Lu
                                
                                et al.
                            
                            (2022). 
                            Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. 
                            New England Journal of Medicine
                            , 386
                            (21)
                            , 1973-1985.
                            https://doi.org/10.1056/nejmoa2202170
                        

Identifiers

DOI: 10.1056/nejmoa2202170
PMID: 35403841
PMCID: PMC9844511

Data Quality

Data completeness: 86%